Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Measures to be taken in case of overdose Symptoms: no cases of overdose have been reported
It is not held on the MHRA register of products with a marketing authorisation and is not approved for any therapeutic indication
JAMA Oncology 10(11), 2024
This means: We have no documented human safety data from a rigorous clinical trial Any safety signals that might have emerged (malignancies, serious adverse events) in the Benoist cohort are unreliable We lost the opportunity to assess safety in the population most likely to benefit (older individuals with cognitive decline) and therefore most likely to reveal adverse effects Athira Pharma False Claims Settlement The January 2025 settlement of False Claims Act allegations against Athira Pharma (the company developing fosgonimeton, the IV version of this mechanism) for $4 million further underscores systemic integrity problems in this research ecosystem
